Skip to main content
PMC home page
Infection and Immunity logoLink to Infection and Immunity
. 1995 Jul;63(7):2706–2713. doi: 10.1128/iai.63.7.2706-2713.1995

Characterization of a recombinant pneumolysin and its use as a protein carrier for pneumococcal type 18C conjugate vaccines.

J Kuo 1, M Douglas 1, H K Ree 1, A A Lindberg 1
PMCID: PMC173362  PMID: 7790088

Abstract

Pneumolysin from Streptococcus pneumoniae was expressed in Escherichia coli as a glutathione S-transferase fusion protein and purified by affinity and hydroxylapatite chromatography. The purified recombinant pneumolysin (rPL), with a molecular mass of 53 kDa, had a specific activity of 3 x 10(5) hemolytic units per mg of protein on rabbit erythrocytes and reacted identically in immunodiffusion with the antisera against native pneumolysin. The rPL was used as a protein carrier to prepare conjugate vaccine with pneumococcal type 18C polysaccharide (PS18C). The PS18C was directly coupled to rPL by reductive animation or was indirectly coupled to rPL via a spacer molecule, adipic acid dihydrazide. The conjugates were nontoxic for mice and guinea pigs at 100 micrograms per dose. The immunogenicity and protective efficacy of both conjugates were tested in mice. A single dose of either of the vaccines elicited a rise in immunoglobulin G antibody production; after two booster injections of the vaccines, statistically significant booster responses (P < 0.001) to both rPL and PS18C were produced. The sera containing the antibodies to rPL were capable of neutralizing the hemolytic activity of rPL to rabbit erythrocytes and the cytotoxicity of rPL to bovine pulmonary endothelial cells. Immunization with the conjugate vaccines conferred statistically significant protection in mice against lethal challenge with type 18C pneumococci.

Full Text

The Full Text of this article is available as a PDF (318.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alexander J. E., Lock R. A., Peeters C. C., Poolman J. T., Andrew P. W., Mitchell T. J., Hansman D., Paton J. C. Immunization of mice with pneumolysin toxoid confers a significant degree of protection against at least nine serotypes of Streptococcus pneumoniae. Infect Immun. 1994 Dec;62(12):5683–5688. doi: 10.1128/iai.62.12.5683-5688.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Anderson P. W., Jr, Stein E. C., Insel R. A. Background and indications for Haemophilus influenzae type b vaccines consisting of capsular antigen coupled to protein carriers. Contrib Microbiol Immunol. 1989;10:115–124. [PubMed] [Google Scholar]
  3. Austrian R. Some observations on the pneumococcus and on the current status of pneumococcal disease and its prevention. Rev Infect Dis. 1981 Mar-Apr;3 (Suppl):S1–17. doi: 10.1093/clinids/3.supplement_1.s1. [DOI] [PubMed] [Google Scholar]
  4. Bajaj S. P., Rapaport S. I., Prodanos C. A simplified procedure for purification of human prothrombin, factor IX and factor X. Prep Biochem. 1981;11(4):397–412. doi: 10.1080/00327488108065531. [DOI] [PubMed] [Google Scholar]
  5. Berry A. M., Paton J. C., Hansman D. Effect of insertional inactivation of the genes encoding pneumolysin and autolysin on the virulence of Streptococcus pneumoniae type 3. Microb Pathog. 1992 Feb;12(2):87–93. doi: 10.1016/0882-4010(92)90111-z. [DOI] [PubMed] [Google Scholar]
  6. Berry A. M., Yother J., Briles D. E., Hansman D., Paton J. C. Reduced virulence of a defined pneumolysin-negative mutant of Streptococcus pneumoniae. Infect Immun. 1989 Jul;57(7):2037–2042. doi: 10.1128/iai.57.7.2037-2042.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Black S. B., Shinefield H. R., Fireman B., Hiatt R. Safety, immunogenicity, and efficacy in infancy of oligosaccharide conjugate Haemophilus influenzae type b vaccine in a United States population: possible implications for optimal use. J Infect Dis. 1992 Jun;165 (Suppl 1):S139–S143. doi: 10.1093/infdis/165-supplement_1-s139. [DOI] [PubMed] [Google Scholar]
  8. Boulnois G. J. Pneumococcal proteins and the pathogenesis of disease caused by Streptococcus pneumoniae. J Gen Microbiol. 1992 Feb;138(2):249–259. doi: 10.1099/00221287-138-2-249. [DOI] [PubMed] [Google Scholar]
  9. Bradford M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976 May 7;72:248–254. doi: 10.1006/abio.1976.9999. [DOI] [PubMed] [Google Scholar]
  10. Brosius J. Plasmid vectors for the selection of promoters. Gene. 1984 Feb;27(2):151–160. doi: 10.1016/0378-1119(84)90136-7. [DOI] [PubMed] [Google Scholar]
  11. Claesson B. A., Schneerson R., Trollfors B., Lagergård T., Taranger J., Robbins J. B. Duration of serum antibodies elicited by Haemophilus influenzae type b capsular polysaccharide alone or conjugated to tetanus toxoid in 18- to 23-month-old children. J Pediatr. 1990 Jun;116(6):929–931. doi: 10.1016/s0022-3476(05)80655-9. [DOI] [PubMed] [Google Scholar]
  12. Donnelly J. J., Deck R. R., Liu M. A. Immunogenicity of a Haemophilus influenzae polysaccharide-Neisseria meningitidis outer membrane protein complex conjugate vaccine. J Immunol. 1990 Nov 1;145(9):3071–3079. [PubMed] [Google Scholar]
  13. Douglas R. M., Paton J. C., Duncan S. J., Hansman D. J. Antibody response to pneumococcal vaccination in children younger than five years of age. J Infect Dis. 1983 Jul;148(1):131–137. doi: 10.1093/infdis/148.1.131. [DOI] [PubMed] [Google Scholar]
  14. Eskola J., Käyhty H., Takala A. K., Peltola H., Rönnberg P. R., Kela E., Pekkanen E., McVerry P. H., Mäkelä P. H. A randomized, prospective field trial of a conjugate vaccine in the protection of infants and young children against invasive Haemophilus influenzae type b disease. N Engl J Med. 1990 Nov 15;323(20):1381–1387. doi: 10.1056/NEJM199011153232004. [DOI] [PubMed] [Google Scholar]
  15. Ferrante A., Rowan-Kelly B., Paton J. C. Inhibition of in vitro human lymphocyte response by the pneumococcal toxin pneumolysin. Infect Immun. 1984 Nov;46(2):585–589. doi: 10.1128/iai.46.2.585-589.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Gray G. R. The direct coupling of oligosaccharides to proteins and derivatized gels. Arch Biochem Biophys. 1974 Jul;163(1):426–428. doi: 10.1016/0003-9861(74)90495-0. [DOI] [PubMed] [Google Scholar]
  17. Hanahan D. Studies on transformation of Escherichia coli with plasmids. J Mol Biol. 1983 Jun 5;166(4):557–580. doi: 10.1016/s0022-2836(83)80284-8. [DOI] [PubMed] [Google Scholar]
  18. Inman J. K., Dintzis H. M. The derivatization of cross-linked polyacrylamide beads. Controlled introduction of functional groups for the preparation of special-purpose, biochemical adsorbents. Biochemistry. 1969 Oct;8(10):4074–4082. doi: 10.1021/bi00838a026. [DOI] [PubMed] [Google Scholar]
  19. Jacques I., Dubray G. Escherichia hermannii (ATCC 33651) polysaccharide-protein conjugates: comparison of two conjugation methods for the induction of humoral responses in mice. Vaccine. 1991 Aug;9(8):559–563. doi: 10.1016/0264-410x(91)90242-x. [DOI] [PubMed] [Google Scholar]
  20. Jacques I., Olivier-Bernardin V., Dubray G. Induction of antibody and protective responses in mice by Brucella O-polysaccharide-BSA conjugate. Vaccine. 1991 Dec;9(12):896–900. doi: 10.1016/0264-410x(91)90010-4. [DOI] [PubMed] [Google Scholar]
  21. Jalonen E., Paton J. C., Koskela M., Kerttula Y., Leinonen M. Measurement of antibody responses to pneumolysin--a promising method for the presumptive aetiological diagnosis of pneumococcal pneumonia. J Infect. 1989 Sep;19(2):127–134. doi: 10.1016/s0163-4453(89)91864-1. [DOI] [PubMed] [Google Scholar]
  22. Jennings H. J., Lugowski C. Immunochemistry of groups A, B, and C meningococcal polysaccharide-tetanus toxoid conjugates. J Immunol. 1981 Sep;127(3):1011–1018. [PubMed] [Google Scholar]
  23. Johnson M. K., Boese-Marrazzo D., Pierce W. A., Jr Effects of pneumolysin on human polymorphonuclear leukocytes and platelets. Infect Immun. 1981 Oct;34(1):171–176. doi: 10.1128/iai.34.1.171-176.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Johnson M. K. Properties of purified pneumococcal hemolysin. Infect Immun. 1972 Nov;6(5):755–760. doi: 10.1128/iai.6.5.755-760.1972. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Kanclerski K., Blomquist S., Granström M., Möllby R. Serum antibodies to pneumolysin in patients with pneumonia. J Clin Microbiol. 1988 Jan;26(1):96–100. doi: 10.1128/jcm.26.1.96-100.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Kanclerski K., Möllby R. Production and purification of Streptococcus pneumoniae hemolysin (pneumolysin). J Clin Microbiol. 1987 Feb;25(2):222–225. doi: 10.1128/jcm.25.2.222-225.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Koskela M. Serum antibodies to pneumococcal C polysaccharide in children: response to acute pneumococcal otitis media or to vaccination. Pediatr Infect Dis J. 1987 Jun;6(6):519–526. doi: 10.1097/00006454-198706000-00006. [DOI] [PubMed] [Google Scholar]
  28. Lee C. J., Fraser B. A., Boykins R. A., Li J. P. Effect of culture conditions on the structure of Streptococcus pneumoniae type 19A(57) capsular polysaccharide. Infect Immun. 1987 Aug;55(8):1819–1823. doi: 10.1128/iai.55.8.1819-1823.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Lee C. J., Lock R. A., Andrew P. W., Mitchell T. J., Hansman D., Paton J. C. Protection of infant mice from challenge with Streptococcus pneumoniae type 19F by immunization with a type 19F polysaccharide--pneumolysoid conjugate. Vaccine. 1994 Aug;12(10):875–878. doi: 10.1016/0264-410x(94)90028-0. [DOI] [PubMed] [Google Scholar]
  30. Leinonen M., Säkkinen A., Kalliokoski R., Luotonen J., Timonen M., Mäkelä P. H. Antibody response to 14-valent pneumococcal capsular polysaccharide vaccine in pre-school age children. Pediatr Infect Dis. 1986 Jan-Feb;5(1):39–44. doi: 10.1097/00006454-198601000-00008. [DOI] [PubMed] [Google Scholar]
  31. Paton J. C., Berry A. M., Lock R. A., Hansman D., Manning P. A. Cloning and expression in Escherichia coli of the Streptococcus pneumoniae gene encoding pneumolysin. Infect Immun. 1986 Oct;54(1):50–55. doi: 10.1128/iai.54.1.50-55.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Paton J. C., Lock R. A., Hansman D. J. Effect of immunization with pneumolysin on survival time of mice challenged with Streptococcus pneumoniae. Infect Immun. 1983 May;40(2):548–552. doi: 10.1128/iai.40.2.548-552.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Paton J. C., Lock R. A., Lee C. J., Li J. P., Berry A. M., Mitchell T. J., Andrew P. W., Hansman D., Boulnois G. J. Purification and immunogenicity of genetically obtained pneumolysin toxoids and their conjugation to Streptococcus pneumoniae type 19F polysaccharide. Infect Immun. 1991 Jul;59(7):2297–2304. doi: 10.1128/iai.59.7.2297-2304.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Peeters C. C., Tenbergen-Meekes A. M., Evenberg D. E., Poolman J. T., Zegers B. J., Rijkers G. T. A comparative study of the immunogenicity of pneumococcal type 4 polysaccharide and oligosaccharide tetanus toxoid conjugates in adult mice. J Immunol. 1991 Jun 15;146(12):4308–4314. [PubMed] [Google Scholar]
  35. Peeters C. C., Tenbergen-Meekes A. M., Haagmans B., Evenberg D., Poolman J. T., Zegers B. J., Rijkers G. T. Pneumococcal conjugate vaccines. Immunol Lett. 1991 Oct;30(2):267–274. doi: 10.1016/0165-2478(91)90036-a. [DOI] [PubMed] [Google Scholar]
  36. Peeters C. C., Tenbergen-Meekes A. M., Poolman J. T., Beurret M., Zegers B. J., Rijkers G. T. Effect of carrier priming on immunogenicity of saccharide-protein conjugate vaccines. Infect Immun. 1991 Oct;59(10):3504–3510. doi: 10.1128/iai.59.10.3504-3510.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Robbins J. B., Austrian R., Lee C. J., Rastogi S. C., Schiffman G., Henrichsen J., Mäkelä P. H., Broome C. V., Facklam R. R., Tiesjema R. H. Considerations for formulating the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within groups. J Infect Dis. 1983 Dec;148(6):1136–1159. doi: 10.1093/infdis/148.6.1136. [DOI] [PubMed] [Google Scholar]
  38. Robbins J. B., Schneerson R. Polysaccharide-protein conjugates: a new generation of vaccines. J Infect Dis. 1990 May;161(5):821–832. doi: 10.1093/infdis/161.5.821. [DOI] [PubMed] [Google Scholar]
  39. Rubins J. B., Duane P. G., Charboneau D., Janoff E. N. Toxicity of pneumolysin to pulmonary endothelial cells in vitro. Infect Immun. 1992 May;60(5):1740–1746. doi: 10.1128/iai.60.5.1740-1746.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Rubins J. B., Duane P. G., Clawson D., Charboneau D., Young J., Niewoehner D. E. Toxicity of pneumolysin to pulmonary alveolar epithelial cells. Infect Immun. 1993 Apr;61(4):1352–1358. doi: 10.1128/iai.61.4.1352-1358.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Schneerson R., Barrera O., Sutton A., Robbins J. B. Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates. J Exp Med. 1980 Aug 1;152(2):361–376. doi: 10.1084/jem.152.2.361. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Schutze M. P., Leclerc C., Jolivet M., Audibert F., Chedid L. Carrier-induced epitopic suppression, a major issue for future synthetic vaccines. J Immunol. 1985 Oct;135(4):2319–2322. [PubMed] [Google Scholar]
  43. Schwartz B. A., Gray G. R. Proteins containing reductively aminated disaccharides. Synthesis and chemical characterization. Arch Biochem Biophys. 1977 Jun;181(2):542–549. doi: 10.1016/0003-9861(77)90261-2. [DOI] [PubMed] [Google Scholar]
  44. Smith D. B., Johnson K. S. Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase. Gene. 1988 Jul 15;67(1):31–40. doi: 10.1016/0378-1119(88)90005-4. [DOI] [PubMed] [Google Scholar]
  45. Taira S., Jalonen E., Paton J. C., Sarvas M., Runeberg-Nyman K. Production of pneumolysin, a pneumococcal toxin, in Bacillus subtilis. Gene. 1989 Apr 30;77(2):211–218. doi: 10.1016/0378-1119(89)90069-3. [DOI] [PubMed] [Google Scholar]
  46. Walker J. A., Allen R. L., Falmagne P., Johnson M. K., Boulnois G. J. Molecular cloning, characterization, and complete nucleotide sequence of the gene for pneumolysin, the sulfhydryl-activated toxin of Streptococcus pneumoniae. Infect Immun. 1987 May;55(5):1184–1189. doi: 10.1128/iai.55.5.1184-1189.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES